Dapagliflozin improves CKD outcomes ‘even without diabetes’

The drug has potential for people with renal disease in need of improved treatment options, investigators say
Medicom Staff writer

AusDoc brings you the latest news from the European Society of Cardiology Congress 2020.

Use of dapagliflozin in patients with chronic kidney disease can improve outcomes in patients with and without type 2 diabetes, trial results show.